Celldex Therapeutics, Inc. (NASDAQ:CLDX) is scheduled to release its earnings data after the market closes on Monday, November 6th. Analysts expect Celldex Therapeutics to post earnings of ($0.27) per share for the quarter.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.05. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The company had revenue of $3.83 million during the quarter, compared to the consensus estimate of $1.21 million. During the same period last year, the company earned ($0.32) EPS. Celldex Therapeutics’s revenue for the quarter was up 175.5% on a year-over-year basis. On average, analysts expect Celldex Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) opened at $2.49 on Friday.

Several research analysts have issued reports on CLDX shares. Cantor Fitzgerald restated a “buy” rating and issued a $9.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. HC Wainwright set a $10.00 price target on shares of Celldex Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Tuesday, July 11th. ValuEngine lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, BidaskClub lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $5.88.

COPYRIGHT VIOLATION NOTICE: “Celldex Therapeutics, Inc. (CLDX) Scheduled to Post Quarterly Earnings on Monday” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/celldex-therapeutics-inc-cldx-scheduled-to-post-quarterly-earnings-on-monday/1676977.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Earnings History for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.